Lundbeck Secures Orphan Designation for Cushing’s Syndrome Drug

Lundbeck’s candidate, Lu AG13909, aims to address the substantial unmet medical need for patients who fail to achieve remission through surgery or standard therapies. Asedebart functions by blocking ACTH from binding to the melanocortin 2 receptor in the adrenal glands, effectively curbing the overproduction of steroids. The company is currently evaluating the compound’s safety and efficacy through ongoing proof-of-concept trials for both Cushing’s disease and congenital adrenal hyperplasia.

Johan Luthman, Lundbeck’s Executive Vice President of R&D, noted that the designation validates both the scientific rationale behind the program and the severity of the condition. In the European Union, this status provides developers with key incentives, including protocol assistance, reduced regulatory fees, and the potential for ten years of market exclusivity upon approval. Asedebart has previously received similar regulatory recognition in the United States and Japan, reinforcing its position as a primary asset in Lundbeck’s expanding portfolio of neuro-rare therapies.